drugset / Trial / NCT01264250

A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers

NCT01264250 ↗

Phase 1 Completed 48 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

In this early phase study, healthy male volunteers will be randomly assigned to one dose of either AZD2927 or placebo. The objective will be to assess the Safety,Tolerability and Pharmacokinetics of AZD2927.

Timeline

Start
2011-01
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2927 Small molecule — Intravenous

Indications

No indication recorded.